Literature DB >> 26251313

Synthesis and antidepressant activities of 4-(substituted-phenyl)tetrazolo[1,5-a]quinazolin-5(4H)-ones and their derivatives.

Hong-Jian Zhang1, Shi-Ben Wang1, Zhe-Shan Quan2.   

Abstract

A series of novel 4-(substituted-phenyl) tetrazolo[1,5-a]quinazolin-5(4H)-ones (6a-x) and their derivatives with tetrazole and other heterocyclic substituents (7-14) were designed, synthesized, and evaluated for antidepressant activities in mice. Pharmacological tests showed that three compounds (6l, 6u, and 6v) at a dose of 50 mg/kg significantly reduced the immobility time in the forced swimming test. The most active compound was 4-(p-tolyl)tetrazolo[1,5-a]quinazolin-5(4H)-one (6v), which decreased the immobility time by 82.69 % at 50 mg/kg. Moreover, 6v did not affect spontaneous activity in the open-field test, and this effect was comparable to the antidepressant effect of fluoxetine. Noradrenaline (NE) and 5-hydroxytryptamine (5-HT) levels in the brains of mice in the test sample groups significantly increased at a dose of 50 mg/kg compared with that in the control group. The monoamine oxidase (MAO) level of all test groups was reduced, but this result was not significantly different between the groups. Therefore, we can infer that their underlying mechanisms may involve the regulation of brain monoamine neurotransmitter homeostasis, based on the detected content of NE, 5-HT, and MAO in mouse brain tissue.

Entities:  

Keywords:  Antidepressant; Monoamine oxidasecontent; Noradrenaline; Open-field test; Quinazolinone

Mesh:

Substances:

Year:  2015        PMID: 26251313     DOI: 10.1007/s11030-015-9623-1

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  27 in total

1.  A synthetic bioisoster of trimethadione and phenytoin elicits anticonvulsant effect, protects the brain oxidative damage produced by seizures and exerts antidepressant action in mice.

Authors:  Valentina Pastore; Cristina Wasowski; Josefina Higgs; Irene C Mangialavori; Luis E Bruno-Blanch; Mariel Marder
Journal:  Eur Neuropsychopharmacol       Date:  2014-05-02       Impact factor: 4.600

2.  Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice.

Authors:  Andrea D E Zomkowski; Adair Roberto S Santos; Ana Lúcia S Rodrigues
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-07-05       Impact factor: 5.067

3.  Antiepileptic Drug Development Program.

Authors:  R J Porter; J J Cereghino; G D Gladding; B J Hessie; H J Kupferberg; B Scoville; B G White
Journal:  Cleve Clin Q       Date:  1984

4.  A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.

Authors:  Michael E Thase; Sara A Corya; Olawale Osuntokun; Michael Case; David B Henley; Todd M Sanger; Susan B Watson; Sanjay Dubé
Journal:  J Clin Psychiatry       Date:  2007-02       Impact factor: 4.384

5.  Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted-3H-quinazolin-4-one as analgesic, anti-inflammatory agents.

Authors:  V Alagarsamy; V Raja Solomon; K Dhanabal
Journal:  Bioorg Med Chem       Date:  2006-09-30       Impact factor: 3.641

Review 6.  [Recent progress in neurobiological mechanisms of depression].

Authors:  Yu-Bo Gao; Liang-Ping Li; Xin-Hong Zhu; Tian-Ming Gao
Journal:  Sheng Li Xue Bao       Date:  2012-08-25

7.  Synthesis and evaluation on anticonvulsant and antidepressant activities of 5-Alkoxy-tetrazolo[1,5-a]quinazolines.

Authors:  Huo-Jian Wang; Cheng-Xi Wei; Xian-Qing Deng; Fu-Lan Li; Zhe-Shan Quan
Journal:  Arch Pharm (Weinheim)       Date:  2009-11       Impact factor: 3.751

8.  The tail suspension test: a new method for screening antidepressants in mice.

Authors:  L Steru; R Chermat; B Thierry; P Simon
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission.

Authors:  Ricardo W Binfaré; Angelo O Rosa; Kelly R Lobato; Adair R S Santos; Ana Lúcia S Rodrigues
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-02-11       Impact factor: 5.067

10.  Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.

Authors:  Robert M Berman; Michael E Thase; Madhukar H Trivedi; James A Hazel; Sabrina Vogel Marler; Robert D McQuade; William Carson; Ross A Baker; Ronald N Marcus
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-24       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.